What 2,500 Sequenced Genomes Say about Humanity’s Future
By Lizzie Wade,
Wired
| 09. 30. 2015
When the geneticist Gonçalo Abecasis stood up in front of a group of scientists in 2007 and proposed sequencing 1,000 genomes from people all over the world, he had no idea how he was going to pull it off. The Human Genome Project had published the first complete map of the human genome just four years earlier, and the technology remained exorbitantly expensive. “Imagine you’ve done ten of these,” Abecasis says today of the number of human genomes that had been sequenced at the time. “The first one cost $3 billion, and the other ones cost several million. And you say, ‘what if we set out to do a thousand?’”
The price wasn’t the only hurdle. “When we first started talking about doing these genome-wide comparisons between populations”—i.e., groups of people from different continents or with different ancestries—“there was a lot of tension,” remembers Abecasis, now at the University of Michigan. That’s because, frankly, “human population” sounds a lot like “race.”
Sequencing the human genome showed that humans are all much more alike than different; genome pioneer J. Craig Venter...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...